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Abstract: Introduction: Osteoarthritis is the most common form of arthritis. It is a slowly 
progressive  joint  disease  typically  seen  in  middle-age  to  elderly  people.  Intra-articular 
injection  of  hyaluronic  acid  is  a  well-documented  treatment  for  knee  osteoarthritis. 
Celebrex
® (celecoxib) is a novel nonsteroidal anti-inflammatory drug, which could help to 
reduce inflammation and to reduce pain. The aim of this study was to evaluate the effects of 
intra-articular injection of celecoxib in a rabbit osteoarthritis model. Methods: Thirty New 
Zealand white rabbits underwent unilateral knee joint surgery using the Hulth technique. 
Six weeks post-surgery, the animals were randomly divided into three groups, and each 
group was respectively given weekly intra-articular injections with Celebrex
®, hyaluronic 
acid and saline. On the sixth week, the results were assessed in rabbit models by gross 
observation, histological evaluation, and expression of IL-1β, TNF-α, MMP-3. Results: In 
the  group  given  Celebrex
®  and  hyaluronic  acid,  the  pathological  changes  in  the  rabbit 
articular  cartilage  improved  significantly,  much  more  than  in  the  saline  group.  The 
statistically significant suppression of IL-1β, TNF-α, MMP-3 was shown in the Celebrex 
group. No significant differences were detected between two treatment groups. Conclusions: 
Intra-articular injection of celecoxib is beneficial for knee osteoarthritis. It might repair and 
protect early osteoarthritis cartilage by delaying cartilage degeneration and impairing the  
 




function of inflammatory mediators, therefore, intra-articular injection of celecoxib can be 
used as an alternative to the current treatment of osteoarthritis. 
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1. Introduction 
Osteoarthritis  (OA)  is  a  degenerative  joint  disease  occurring  mostly  occurs  in  the  knee  and 
commonly  seen  in  middle-aged  and  elderly  adults  [1].  Knee  OA  is  a  degenerative  disease  that 
manifests as knee joint dysfunction that results from joint destruction and deformation. It’s caused by 
primary  and  secondary  degeneration  and  structural  disturbance  of  knee  joint  cartilage,  and  is 
accompanied by subchondral bone hyperplasia and cartilage denudation. The pain and disability due to 
OA significantly affects patients’ quality of life. Therefore, the importance and impact of OA have 
recently been compared to the threat of cardiovascular attack [2]. 
 
The  treatment  for  early  OA  mainly  consists  of  relieving  its  clinical  symptoms,  delaying  joint 
degeneration.  Non-surgical  modalities  for  OA  management  include  weight  loss,  exercise,  activity 
modification,  assistive  devices,  non-steroidal  anti-inflammatory  drugs  (NSAIDs),  analgesics,  and  
intra-articular hyaluronic acid (HA) preparations [3]. Intra-articular treatment currently represents the 
standard method for affecting joint pain and inflammation in patients with arthritides and so-called 
activated  osteoarthritis  accompanied  by  inflammatory  processes  [4].  Intra-articular  treatment  is 
effective  in  relieving  pain  and  prolonging  degeneration,  therefore  it  has  been  one  of  the  main 
treatments for osteoarthritis [5,6]. Celebrex
® (celecoxib, Pfizer Inc., NY, USA) is a type of NASID and 
a novel selective COX-2 inhibitor, which can selectively suppress inflammation relevant COX-2, while 
preserving the physical functions of COX-1. This drug avoids gastrointestinal complications caused by 
traditional  NSAIDs.  In  this  study,  we  attempted  to  determine  whether  intra-articular  injection  of 
celecoxib would have the anti-inflammatory advantages, while also maintaining its protective effect on 
articular cartilage, as well as HA, in a rabbit OA model. 
2. Materials and Methods 
2.1. Study Design  
Thirty New Zealand white rabbits (irrespective of sex), each weighing 2.2–3.0 Kg, were provided by 
the  Experimental  Animal  Center  of  University.  Under  anesthesia  with  10%  chloral  hydrate  
(4 mL/kg body weight), OA models were established by performing unilateral knee joint surgery as 
described by Hulth [7]. Through a medial parapatellar incision, knee joints were opened, and anterior 
and posterior cruciate ligaments were transected and medial meniscus excised. Postoperatively, all 
animals were permitted free cage activity. Six weeks after the surgery, the animals were divided into 
three groups (n = 10 in each group): celecoxib group; HA group and control group. For animals in the 
treatment groups, 0.3 mL of 0.4% celecoxib, or 1% HA (Baker Norton Co., Kunming, China) was 
injected weekly into the affected joint for five weeks, while 0.3 mL of normal saline was administered 




2.2. Gross Pathology Observation and Histological Evaluation 
After five weeks, the rabbits were sacrificed and femoral condyles were collected for observation. 
After macroscopic examination, isolated samples were fixed with 10% neutral buffered formalin and 
decalcified with 20% EDTA solution for further histological evaluation. The decalcified samples were 
embedded in paraffin, and standard frontal sections of 5 µm sections were prepared and stained with 
hematoxylin-eosin in the lateral part of the femoral condyle cartilage according to gross observation. 
The weight bearing area of the femoral condyle was delimited and cartilage degradation was assessed 
using the Mankin’s scoring system [8]. All sections were graded by three independent observers that 
were kept unaware of the treatment groups. 
2.3. Measurement of IL-1β and TNF-α in Synovial Fluid 
At the five-week time point, synovial fluid was collected from the operated knee before sacrifice. 
The samples were stored at −30° C until assayed. The contents of IL-1β and TNF-α in synovial fluid 
were measured by ELISA kits (Senxiong Co., Shanghai, China). 
2.4. Measurement of mRNA Expression of MMP-3  
After  sacrifice,  synoviums  of  the  operated  knee  were  harvested  for  measurement  of  mRNA 
expression of MMP-3. Primers were designed and synthesized. Total RNA was extracted, measured, 
reverse  transcripted,  and  amplified  by  reverse  transcription-  polymerase  chain  reaction  (RT-PCR) 
(Perkin-Elmer, Norwalk, USA). The PCR products were separated on 1.5% agarose gels and visualized 
by ethidium bromide staining. Ethidium bromide-stained gels were digitally photographed. The relative 
levels of mRNAs were normalized to the mean gray value of β-actin and then expressed as relative 
mRNA value for each specimen.  
2.5. Statistical Analysis 
The data was processed by the SPSS11.5 software package and expressed as x  ±  s. Differences 
between groups were compared by t-test and considered to be statistically significant if P < 0.05. 
3. Results 
3.1. Gross Pathological Observation 
Normal rabbit knee articular cartilage is smooth and lustrous with a light blue-white color. In the 
control  group,  cartilage  appeared  to  be  yellowish-white,  lackluster  and  its  appearance  displayed 
significant  cracks  and  cartilage  defects;  osteophyte-like  structures  were  observed  in  the  femoral 
condyle and both sides of the tibial plateau (Figure 1A). In the treatment groups, both the celecoxib 
group and HA group, cartilage lesions associated with OA were clearly seen, but the severity was 
milder than in the control group (Figure 1B, C).  
 




Figure 1. Gross pathological observation of the femoral condyle in saline (A), celecoxib (B) 
and HA (C) groups.  
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3.2. Histological Evaluation 
In  the  control  group,  findings  included  degenerative/necrotic  and  disarranged  chondrocytes, 
significant  ulcerous lesions  in  the deep cartilage layer, considerable inflammatory exudates, newly 
formed capillaries and fibroblast proliferation, fibroplasia in the bottom of the ulcers, and degenerative 
deep  chondrocytes  (Figure  2A).  In  both  two  treatment  groups,  observations  included 
degenerative/necrotic  or  shed  perichondrium,  degenerative/necrotic  and  disarranged  superficial 
chondrocytes,  and  a  small  amount  of  inflammatory  exudates,  erosion,  and  sparse  capillary  and 
fibroblast proliferation (Figure 2B, C). Mankin’s scores in the celecoxib (2.1 ±  0.5) and HA (2.4 ±  0.6) 
groups were significantly lower than in the control group (6.9 ±  0.8) (P < 0.05), as seen in Figure 3. 
However, no significant differences between the two treatment groups were observed. 
Figure 2. Histological findings of the femoral condyles in saline (A); celecoxib (B) and  
HA (C) groups. 
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Figure 3. Histological scores of cartilage according to Mankin scoring system. * P < 0.05 
compared to saline group. 




3.3. IL-1β and TNF-α in Synovial Fluid  
Figure 4 shows the results of the measurements of IL-1β and TNF-α in synovial fluid from each 
group. Differences in both IL-1β and TNF-α contents were significant between treatment and control 
groups (P < 0.05), but not significant between the three treatment groups (P > 0.05). 
Figure 4. Contents of IL-1β and TNF-α in synovial fluid. * P < 0.05 compared to saline group. 
 
3.4. mRNA Expression of MMP-3  
As shown in Figure 5, there was a statistically significant decrease in mRNA expression of MMP-3 
in  the  celecoxib  group  (P  <  0.05),  comparing  to  control  group  (0.58  ±   0.23).  However,  it  did  not 
significantly differ between the two treatment groups (celecoxib 0.31 ±  0.14, HA 0.33 ±  0.16) (P > 0.05). 
Figure 5. mRNA expression of MMP-3 in synovium. * P < 0.05 compared to saline group. 
 
4. Discussion 
The exact pathogenesis of OA remains unclear so far. Generally, it is an articular cartilage injury 




and subchondral bone. This is due to a biomechanical disorder induced by interactions between various 
biological factors and mechanical injury factors. Many studies have confirmed that several biological 
factors are involved in the development of OA, including IL-1β, TNF-α, TGF-β, MMPs and NO. IL-1β 
and TNF-α are found to be important regulators of inflammatory reaction [9,10]. 
IL-1β is one of the most important cytokines responsible for destruction of articular cartilage. It 
functions  by:  (1)  mediating  the  most  effective  destruction  of  cartilage;  (2)  regulating  bone  
re-absorption; (3) enhancing the destructive inflammatory process of OA by stimulating the production 
of  IL-8  in  synovial  tissue  macrophages,  fibroblasts  and  chondrocytes;  (4)  promoting  scarring  and 
fibrosis by directly or indirectly stimulating fibroblast proliferation, and (5) prolonging the survival of 
neutrophils and boosting the inflammatory process. TNF-α is only 3% homologous with IL-1β. The 
biological activity of TNF-α is 100 times lower than that of IL-1β, which cannot activate the murine T 
cell  effect.  TNF-α  may  induce  the  production  of  other  cytokines  including  IL-1β  and 
monocyte/granulocyte stimulating factor, while IL-1β may increase the activity of TNF-α. There is a 
synergistic effect between TNF-α and IL-1β that may mediate destruction of joint tissues [11]. In this 
study, we found that the content of TNF-α and IL-1β was significantly suppressed in the celecoxib 
group in comparison to that in the control group injected with saline. The results suggest that celecoxib 
may suppress the inflammatory response in inflamed joints by inhibiting the expression of TNF-α  
and IL-1β.  
HA is a main component in synovial fluid and cartilage matrix. HA in synovial fluid is primarily 
produced by type B synovial lining cells. A normal concentration of normal HA in synovial fluid is 
critical for the maintenance of joint function
 [12]. Intra-articular treatment with HA for OA knee pain is 
widely  accepted  [13].  This  modality  not  only  replenishes  the  intra-articular  HA,  but  also  inhibits 
inflammatory mediators’ synthesis, relieves joint pain, postpones the development osteoarthritis [14,15]. 
Our study indicated that celecoxib injection might repair and protect against early OA cartilage by 
delaying cartilage degeneration via inhibiting MMP-3 expression as well as HA group. It was also 
showed in our macroscopic and histological analyses. Since MMP-3 has the potent ability to degrade 
the proteoglycan of cartilage, MMP-3 is recognized as an enzyme that plays a part in the destruction of 
cartilage and bone in OA [16]. The results of this study demonstrated that the level of MMP-3 was 
elevated and sustained in the control group treated by injecting saline, whereas elevation of MMP-3 
levels was significantly suppressed in the celecoxib and HA groups. However, there is not a significant 
difference in these two treatment groups. Therefore, it is expected that both of celecoxib and HA would 
be beneficial in the prevention of cartilage damage, as reflected by a reduction in MMP-3 levels. 
5. Conclusions 
In summary, our results suggest that intra-articular injection of celecoxib is an effective therapeutic 
method in an OA model. Celecoxib might not only provide substantially benefits to OA by suppressing 
of the levels of TNF-α and IL-1, but also maintain cellular activity and extracellular matrix synthesis by 
reducing MMP-3 synthesis. It could protect the cartilage matrix from degradation with correspondingly 
improved efficiency observed in the macroscopic and histological analyses. This novel therapeutic 
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